On Monday, Novo Nordisk announced that the results from its Phase 3 trial investigating semaglutide as a treatment for Alzheimer’s “did not confirm the superiority of semaglutide versus placebo in the reduction of progression,” of the disease, according to the press release. Monday’s announcement had a silver lining. That is, the treatment did result in…
PurMinds believes psychedelics hold promise for neurological conditions
PurMinds believes psychedelics hold promise for neurological conditions Interest in psychedelics has ratched up in recent years and a growing number of drug companies are beginning to explore their potential to treat everything from depression to neurodegeneration. “It is a really really exciting time,” said Aron Buchman, chief strategy officer, PurMinds BioPharma, which is exploring…
Athira Pharma faces shareholder rights investigations
A growing number of law firms are investigating claims of securities fraud associated with Athira Pharma (NSDQ:ATHA), a clinical-stage biopharma focused on small molecules targeting neurodegeneration. Its lead therapeutic candidate, ATH-1017, targets dementia associated with Alzheimer’s and Parkinson’s. Law firms investigating potential securities fraud claims involving the company include the following: Ademi (Milwaukee). Block &…